Abstract: The present application provides that synthetic retinoid compounds are useful in methods of treating bacterial infections, such as a bacterial infection caused by S. aureus, methicillin-resistant S. aureus (MRSA), vancomycin-resistant S. aureus (VRSA), E. faecalis, E. faecium, B. subtilis, and B. anthracis. The present application also provides a tricyclic fluoroquinolone compound, Z3060, useful in methods of treating bacterial infections, such as a bacterial infection caused by S. aureus, methicillin-resistant S. aureus (MRSA), vancomycin-resistant S. aureus (VRSA), E. spp., K. pneumoniae, P. aeruginosa, A. baumannii, E. faecium, and E. faecalis. Also provided herein is a gold compound, auranofin, useful in treating bacterial and fungal infections, such as a fungal infection caused by C. albicans, C. parapsilosis, C. tropicalis, C. glabrata, and C. neoformans.

Abstract: The present application provides compounds of formula: Methods of using these compounds for killing bacterial growth and treating bacterial infections are also provided.

Abstract: The present application provides compounds and methods for treating bacterial infections, including bacterial infections caused by MRSA.

Abstract: The present application provides compounds and methods of treating bacterial infection, including bacterial infection caused by P. acnes.

Abstract: The present application provides compounds and methods of treating bacterial infection, including bacterial infection caused by P. acnes.

Abstract: The present application provides compounds of formula: Methods of using these compounds for killing bacterial growth and treating bacterial infections are also provided.

Abstract: The present application provides compounds and methods of treating bacterial infection, including bacterial infection caused by P. acnes.

Abstract: The present application provides that synthetic retinoid compounds are useful in methods of treating bacterial infections, such as a bacterial infection caused by S. aureus, methicillin-resistant S. aureus (MRSA), vancomycin-resistant S. aureus (VRSA), E. faecalis, E. faecium, B. subtilis, and B. anthracis. The present application also provides a tricyclic fluoroquinolone compound, Z3060, useful in methods of treating bacterial infections, such as Sa bacterial infection caused by S. aureus, methicillin-resistant S. aureus (MRSA), vancomycin-resistant S. aureus (VRSA), E. spp., K. pneumoniae, P. aeruginosa, A. baumannii, E. faecium, and E. faecalis. Also provided herein is a gold compound, auranofin, useful in treating bacterial and fungal infections, such as a fungal infection caused by C. albicans, C. parapsilosis, C. tropicalis, C. glabrata, and C. neoformans.

Abstract: Methods of treating a fungal infection in a subject, the method comprising administering to the subject a modified saponin.

Abstract: The invention features compounds that have antibacterial activity, their use for the treatment of bacterial infections, screening methods that use whole animals or plant seedlings to identify compounds that inhibit a pathogen in the animal or plant, and screening methods to identify compounds that increase the lifespan of an organism.

Abstract: Methods of treating a fungal infection in a subject, the method comprising administering to the subject a modified saponin.

Abstract: Methods of treating a fungal infection in a subject, the method comprising administering to the subject a modified saponin.

Abstract: The invention features compounds that have antibacterial activity, their use for the treatment of bacterial infections, screening methods that use whole animals or plant seedlings to identify compounds that inhibit a pathogen in the animal or plant, and screening methods to identify compounds that increase the lifespan of an organism.

Abstract: This disclosure relates to compositions including certain compounds identified by a quantitative, high throughput assay to be effective in inhibiting the ability of a bacterium to kill a host organism, as well as methods for using these compounds for treating bacterial infections.

Abstract: This disclosure relates to compositions including certain compounds identified by a quantitative, high throughput assay to be effective in inhibiting the ability of a bacterium to kill a host organism, as well as methods for using these compounds for treating bacterial infections.

Abstract: Methods of treating a fungal infection in a subject, the method comprising administering to the subject a modified saponin.

Abstract: Methods of treating a fungal infection in a subject, the method comprising administering to the subject a modified saponin.

Abstract: The present invention relates to genetically modified plant cells that have reduced expression or activity of at least one amino acid efflux transporter and/or at least one mineral efflux transporter compared to levels of expression or activity of the at least one amino acid efflux transporter or mineral efflux transporter in an unmodified plant cell. The present invention also relates to genetically modified plant cells that have increased expression or activity of at least one amino acid influx transporter and/or at least one mineral influx transporter compared to levels of expression or activity of the at least one amino acid influx transporter or mineral influx transporter in an unmodified plant cell.

Abstract: Methods of treating a fungal infection in a subject, the method comprising administering to the subject a modified saponin.

Abstract: This disclosure relates to compositions including certain compounds identified by a quantitative, high throughput assay to be effective in inhibiting the ability of a bacterium to kill a host organism, as well as methods for using these compounds for treating bacterial infections.